Sermonix Pharmaceuticals Inc. Report issue

For profit Phase 3
Founded: Columbus Ohio United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04432454
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Sermonix Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

abemaciclib (verzenio) (2 trials)

fulvestrant (faslodex) (1 trial)

lasofoxifene (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3